Multiple Sclerosis (Central Nervous System) - Drugs in Development, 2021

November 2021 | 1320 pages | ID: M0A6479D9F2FEN
Global Markets Direct

Abstracts

Multiple Sclerosis (Central Nervous System) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Sclerosis - Drugs In Development, 2021, provides an overview of the Multiple Sclerosis (Central Nervous System) pipeline landscape.

Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord, and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue, and slurred speech. The predisposing factors include age, gender, family history and certain infections.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Sclerosis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 2, 18, 30, 48, 5, 208, 52 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 43 and 1 molecules, respectively.

Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Sclerosis (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Multiple Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Multiple Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Multiple Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Sclerosis (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Multiple Sclerosis (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Multiple Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Multiple Sclerosis - Overview
Multiple Sclerosis - Therapeutics Development
Multiple Sclerosis - Therapeutics Assessment
Multiple Sclerosis - Companies Involved in Therapeutics Development
Multiple Sclerosis - Drug Profiles
Multiple Sclerosis - Dormant Projects
Multiple Sclerosis - Discontinued Products
Multiple Sclerosis - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Multiple Sclerosis, 2021 .
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021 .
Number of Products by Stage and Molecule Type, 2021 .
Multiple Sclerosis - Pipeline by 4D Pharma Plc, 2021 .
Multiple Sclerosis - Pipeline by AB Science SA, 2021 .
Multiple Sclerosis - Pipeline by Abata Therapeutics, 2021
Multiple Sclerosis - Pipeline by AbbVie Inc, 2021
Multiple Sclerosis - Pipeline by Abeome Corp, 2021 .
Multiple Sclerosis - Pipeline by Abion Inc, 2021
Multiple Sclerosis - Pipeline by Abivax SA, 2021 .
Multiple Sclerosis - Pipeline by Abreos Biosciences Inc, 2021
Multiple Sclerosis - Pipeline by Accure Therapeutics SL, 2021 .
Multiple Sclerosis - Pipeline by Aequus Pharmaceuticals Inc, 2021
Multiple Sclerosis - Pipeline by Affectis Pharmaceuticals AG, 2021
Multiple Sclerosis - Dormant Projects, 2021
Multiple Sclerosis - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Multiple Sclerosis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021